Exact Sciences Raises FY2025 Sales Guidance from $3.130B-$3.170B to $3.220B-$3.235B vs $3.156B Est
Author: Benzinga Newsdesk | November 03, 2025 04:11pm
2025 outlook
The Company has updated its full-year 2025 revenue and adjusted EBITDA guidance:
| | Prior guidance | | November 3 update | | Change at midpoint | | Y/Y growth rate |
| Total revenue | $3.130 - $3.170 billion | | $3.220 - $3.235 billion | | $77.5 million | | 17% |
| Screening | $2.440 - $2.470 billion | | $2.510 - $2.520 billion | | $60.0 million | | 20% |
| Precision Oncology | $690 - $700 million | | $710 - $715 million | | $17.5 million | | 9% |
| Adjusted EBITDA | $455 - $475 million | | $470 - $480 million | | $10.0 million | | 47% |
Posted In: EXAS
